Funded Projects › HORIZON
Yellow4FLAVI · Deconstructing the protective immunity of yellow fever virus 17D to inform flavivirus vaccine design
While endemic to the tropics, flaviviruses like Zika, dengue, West Nile or yellow fever virus are re-emerging pathogens of global health concern. Climate change and urbanization have largely contributed to the dissemination of their mosquito vector and Europe has in recent years been regularly confronted with autochthonous cases. Few vaccines are licensed to prevent flavivirus disease, but the yellow fever 17D (YF17D) vaccine has a unique track record of efficiency and safety. Intriguingly, despite its success, how YF17D induces immunity remains poorly understood. The YELLOW4FLAVI consortium aims to fill the gaps in our understanding of the mechanism of action of this vaccine by linking the structure of the viral particle to the resulting host immune response, in order to learn about optimal vaccine design for flaviviruses in general. Since social acceptance of vaccines is critical for their success, we will also develop optimal communication methods. This will provide us with the tools to tailor vaccine design not only to achieve optimal immune protection, but also to facilitate actual implementation.We are molecular and structural virologists, cell biologists, immunologists, computational scientists, clinicians, and social scientists assembled in a tight collaborative network. To pursue our goal of obtaining a blueprint for determinants of long-lasting immunity for flavivirus vaccine candidates, we will use cutting-edge technologies like cryo-EM, super resolution microscopy, spatial transcriptomics, high-dimensional spectral flow cytometry, single-cell RNA sequencing, advanced cell engineering, small animal models, and clinical studies. In a unique manner, the consortium thereby follows a thread of events from the early response at the site of vaccine injection to the population perception of vaccination, harnessing an enhanced understanding of one of the most successful vaccines of mankind for the development of novel lines of defense against new and old threats.
Consortium · 14 organisations
INSTITUT PASTEUR
FR · €1,744,925
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
DE · €1,997,048
STICHTING AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT
NL · €151,255
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
FR · €278,375
CORPORACION CENTRO INTERNACIONAL DE ENTRENAMIENTO E INVESTIGACIONES MEDICAS
CO · €697,239
KLINIKUM DER LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN
DE
UNIVERSITA DEGLI STUDI DI PADOVA
IT · €294,291
CHARITE - UNIVERSITAETSMEDIZIN BERLIN
DE · €601,828
ISTITUTO ZOOPROFILATTICO SPERIMENTALE DELL'ABRUZZO E DEL MOLISE G CAPORALE
IT · €360,156
OMNISCOPE LIMITED
MT · €534,015
IMMUNEWATCH BV
BE · €328,733
UNIVERSITATSKLINIKUM ERLANGEN
DE · €727,350
KATHOLIEKE UNIVERSITEIT LEUVEN
BE · €370,325
TURUN YLIOPISTO
FI · €459,241
Research fields
← Find collaborators and more funded projects
Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.